Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Transmedics Group Inc (NASDAQ: TMDX) closed at $117.43 in the last session, down -2.57% from day before closing price of $120.53. In other words, the price has decreased by -$2.57 from its previous closing price. On the day, 0.64 million shares were traded. TMDX stock price reached its highest trading level at $121.62 during the session, while it also had its lowest trading level at $116.1861.
Ratios:
We take a closer look at TMDX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 230.73. For the most recent quarter (mrq), Quick Ratio is recorded 9.17 and its Current Ratio is at 9.86. In the meantime, Its Debt-to-Equity ratio is 1.63 whereas as Long-Term Debt/Eq ratio is at 1.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Evercore ISI on September 16, 2025, initiated with a Outperform rating and assigned the stock a target price of $155.
On September 04, 2025, Stifel started tracking the stock assigning a Hold rating and target price of $115.
JP Morgan Downgraded its Overweight to Neutral on December 17, 2024, whereas the target price for the stock was revised from $116 to $75.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 06 ’25 when Hassanein Waleed H bought 8,400 shares for $118.68 per share. The transaction valued at 996,912 led to the insider holds 477,759 shares of the business.
Hassanein Waleed H bought 8,475 shares of TMDX for $985,209 on Aug 07 ’25. The President & CEO now owns 486,234 shares after completing the transaction at $116.25 per share. On Aug 04 ’25, another insider, Basile Edward M, who serves as the Director of the company, sold 4,143 shares for $125.51 each. As a result, the insider received 519,988 and left with 2,866 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 4003230464 and an Enterprise Value of 4121477632. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 60.72, and their Forward P/E ratio for the next fiscal year is 41.76. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.10. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.53 while its Price-to-Book (P/B) ratio in mrq is 12.57. Its current Enterprise Value per Revenue stands at 7.757 whereas that against EBITDA is 41.091.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.09, which has changed by -0.18767291 over the last 52 weeks, in comparison to a change of 0.15535986 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $163.00, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 1.13%, while the 200-Day Moving Average is calculated to be 22.78%.
Shares Statistics:
According to the various share statistics, TMDX traded on average about 1.06M shares per day over the past 3-months and 1004020 shares per day over the past 10 days. A total of 34.04M shares are outstanding, with a floating share count of 32.94M. Insiders hold about 3.36% of the company’s shares, while institutions hold 109.08% stake in the company. Shares short for TMDX as of 1756425600 were 8269364 with a Short Ratio of 7.77, compared to 1753920000 on 7669931. Therefore, it implies a Short% of Shares Outstanding of 8269364 and a Short% of Float of 41.68.
Earnings Estimates
As of right now, 7.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.41, with high estimates of $0.47 and low estimates of $0.29.
Analysts are recommending an EPS of between $2.58 and $1.73 for the fiscal current year, implying an average EPS of $2.26. EPS for the following year is $2.83, with 8.0 analysts recommending between $3.55 and $2.2.
Revenue Estimates
According to 9 analysts,. The current quarter’s revenue is expected to be $145.33M. It ranges from a high estimate of $148.6M to a low estimate of $140.5M. As of. The current estimate, Transmedics Group Inc’s year-ago sales were $108.76MFor the next quarter, 9 analysts are estimating revenue of $155.14M. There is a high estimate of $159.8M for the next quarter, whereas the lowest estimate is $148.61M.
A total of 11 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $605M, while the lowest revenue estimate was $582.2M, resulting in an average revenue estimate of $599.14M. In the same quarter a year ago, actual revenue was $441.54MBased on 11 analysts’ estimates, the company’s revenue will be $723.65M in the next fiscal year. The high estimate is $764M and the low estimate is $687.4M.
